JUNIPER PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-23: Form 8-K; Period of report 2016-12-19; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
- 2016-11-16: Form 8-K; Period of report 2016-11-10; Description 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; Details 1.01.
- 2016-11-15: Form 8-K; Period of report 2016-11-15; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-10-24: Form 8-K; Period of report 2016-10-18; Description 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review; Details 4.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-23 | 8-K | 2016-12-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On December 19, 2016, Juniper Pharmaceuticals, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Jeffrey Young, pursuant to which Mr. Young will serve as the Company’s new Vice President, Finance, Chief Financial Officer and Treasurer, effective January 1, 2017. 7.01 On December 20, 2016, the Company issued a press release entitled “Juniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial Officer”, announcing that Mr. Young will be joining the Company as its new Chief Financial Officer to succeed George O. Elston. | d312077d8k.htm |
| 2016-11-16 | 8-K | 2016-11-10 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 (a) Entry Into A Material Definitive Agreement. 7.01 On November 15, 2016, the Company issued a press release related to the Amendments. | d298306d8k.htm |
| 2016-11-15 | 8-K | 2016-11-15 | 2.02 Results of Operations and Financial Condition | 2.02 On November 15, 2016, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period ending September 30, 2016, entitled “Juniper Pharmaceuticals Reports Third Quarter 2016 Financial Results” (the “Press Release”). | d286727d8k.htm |
| 2016-10-24 | 8-K | 2016-10-18 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 (a) Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. | d250148d8k.htm |
| 2016-08-18 | 8-K | 2016-08-17 | 7.01 Regulation FD Disclosure | 7.01 On August 17, 2016, Juniper Pharmaceuticals, Inc. issued a press release titled “Juniper Pharmaceuticals Reports Results from Phase 2b Clinical Trial of COL-1077 Lidocaine Vaginal Gel in Gynecologic Procedure Pain.” A copy of the press release is furnished and attached as Exhibit 99.1 hereto and is incorporated herein by reference. | d243629d8k.htm |
| 2016-08-04 | 8-K | 2016-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2016, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period ending June 30, 2016, entitled “Juniper Pharmaceuticals Reports Second Quarter 2016 Financial Results” (the “Press Release”). | d237663d8k.htm |
| 2016-07-28 | 8-K | 2016-07-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On July 27, 2016, the stockholders of Juniper Pharmaceuticals, Inc. (the “Company”) approved the Amended and Restated 2015 Long-Term Incentive Plan (the “Amended Plan”) at the 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”). 5.07 At the 2016 Annual Meeting, four proposals were submitted to the stockholders of the Company. | d210709d8k.htm |
| 2016-07-20 | 8-K | 2016-07-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On July 19, 2016, Juniper Pharmaceuticals, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Alicia Secor, pursuant to which Ms. Secor will serve as the Company’s new President and Chief Executive Officer. 7.01 On July 20, 2016, the Company issued a press release entitled “Juniper Pharmaceuticals Appoints Alicia Secor President and Chief Executive Officer,” announcing that Ms. Secor will be joining the Company as its new President and Chief Executive Officer to succeed Frank C. Condella, Jr., who is resigning. | d224513d8k.htm |
| 2016-06-15 | 8-K | 2016-06-13 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On June 13, 2016 (the “Dismissal Date”), Juniper Pharmaceuticals, Inc. (the “Company”) dismissed BDO USA, LLP (“BDO”) as the Company’s independent registered public accounting firm. | d214176d8k.htm |
| 2016-06-02 | 8-K | 2016-06-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On June 2, 2016, Juniper Pharmaceuticals Inc. (the “Company”) announced that Frank C. Condella, Jr. plans to retire as the Company’s President and Chief Executive Officer later this year, when his successor is appointed. 7.01 On June 2, 2016, the Company issued a press release announcing Mr. Condella’s planned retirement. | d204580d8k.htm |
| 2016-05-04 | 8-K | 2016-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2016, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period ending March 31, 2016, entitled “Juniper Pharmaceuticals Reports First Quarter 2016 Financial Results” (the “Press Release”). | d191771d8k.htm |
| 2016-03-24 | 8-K | 2016-03-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 23, 2016, the Board of Directors (the “Board”) of Juniper Pharmaceuticals, Inc. (the “Company”) appointed Dr. Mary Ann Gray as a new director of the Company, upon the recommendation of its Nominating and Governance Committee, effective immediately. | d110555d8k.htm |
| 2016-03-10 | 8-K | 2016-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2016, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month and twelve-month periods ending December 31, 2015, entitled “Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results” (the “Press Release”). | d159021d8k.htm |